AMF Tjanstepension AB Makes New $10.61 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

AMF Tjanstepension AB bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 32,537 shares of the biopharmaceutical company’s stock, valued at approximately $10,610,000.

Other institutional investors and hedge funds have also modified their holdings of the company. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth $27,000. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $42,000. Washington Trust Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 61 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 77.7% during the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares in the company, valued at approximately $11,405,673.55. The trade was a 8.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,405 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the sale, the executive vice president owned 27,438 shares in the company, valued at approximately $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last 90 days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $456.35 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The firm’s fifty day moving average is $441.57 and its two-hundred day moving average is $338.75. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ALNY shares. Piper Sandler lifted their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Saturday, September 27th. Scotiabank lifted their target price on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research note on Friday, August 1st. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 target price on the stock in a research note on Monday, August 4th. Finally, Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Twenty-four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $439.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.